Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
a benzodiazepine drug · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| a benzodiazepine drug | DRUG | - |
Inclusion Criteria: * Complete Study 04-001-01 * Able to take the medication for 9 months * Understand and sign the Informed Consent * Comply with all study-related procedures * Women of child bearing potential must have a confirmed negative urine pregnancy test * Lack of clinically significant abn...
The benzodiazepine drug is used for anxiety disorder in adults. It is being developed as a small molecule treatment in the psychiatry therapeutic area. The drug is currently in Phase 3 clinical development, meaning it is investigational and has not yet been approved by regulatory authorities.
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is developing the benzodiazepine drug. The company is conducting clinical trials for this investigational treatment for anxiety disorder. The drug is in Phase 3 development, and Jazz Pharmaceuticals is the sponsor of the ongoing clinical program.
The benzodiazepine drug is in Phase 3 clinical development for anxiety disorder. It is an investigational small molecule treatment that has not been approved by regulatory authorities. One Phase 3 clinical trial has been completed, and the drug remains under clinical investigation.
The benzodiazepine drug has one completed Phase 3 clinical trial, NCT00106860, titled "A Long-Term Study Continuing on From Study 04-001-01 of an Experimental Medication in Adults With Anxiety Disorder." This trial enrolled 158 participants in the United States and included healthy volunteers.
The benzodiazepine drug is not FDA approved. It is an investigational treatment for anxiety disorder currently in Phase 3 clinical development. The completed Phase 3 trial, NCT00106860, evaluated the drug in adults, but the drug has not received regulatory approval.